TNBC recurrence: what to know

A single recurrence-rate figure cannot describe one person's outlook. Your oncology team considers the original cancer stage, whether lymph nodes were involved, the treatments received, and results from treatment when discussing your situation.

Recurrence means breast cancer has returned after treatment. It may return in the breast or nearby area, or it may be found elsewhere in the body. These situations are assessed differently, so the location and any new test results matter.

Triple-negative breast cancer does not have estrogen, progesterone, or HER2 targets. That biology shapes treatment planning and follow-up conversations. Risk is not a prediction that cancer will return; it is one part of planning surveillance and understanding symptoms.

Keep scheduled follow-up visits and tell the team about changes that persist or become worse. Bring a current list of medicines, previous treatment details, and questions about which symptoms should prompt a call between visits.

If recurrence is being evaluated or discussed, ask what tests are intended to clarify and when results will be reviewed. Treatment choices can include chemotherapy, immunotherapy, or PARP inhibitor therapy in selected situations; the suitable option depends on the cancer and your medical history.

Contact your oncology team promptly for a new breast or chest-wall lump, unexplained persistent bone pain, ongoing shortness of breath, new neurological symptoms, or a change that does not settle. These symptoms have many possible causes, but they deserve timely assessment after breast cancer treatment.

Seek urgent medical care for severe breathing difficulty, sudden weakness, confusion, or a severe new headache, especially if symptoms begin abruptly.

What features of my original TNBC most affect my individual recurrence risk? What follow-up plan is appropriate for me, and which symptoms should lead me to contact the clinic? If a new finding needs investigation, what will each test be looking for?